<DOC>
	<DOCNO>NCT00826618</DOCNO>
	<brief_summary>Uveitic Cystoid Macular Edema ( CME ) major cause visual loss associate uveitis . Systemic and/or local corticosteroid therapy systemic immunosuppression steroid-sparing agent cyclosporine , methotrexate , azathioprine , others , effectively treat uveitis associate CME many patient . However , many case , CME persist spite adequate suppression uveitis . No consensus exist best treat case . The addition immunosuppressive agent appear little effect form CME . Oral corticosteroid useful , high dosage prolong use associate serious side-effects . Periocular intravitreal corticosteroid injection associate well-known , significant side effect glaucoma cataract formation . Vascular endothelial growth factor ( VEGF ) suspect play role loss vascular integrity eye know induced inflammatory cytokine , interleukin interleukin ( IL ) -1Î² IL-6 , elevate intraocularly uveitis . In addition , demonstrate aqueous VEGF concentration statistically significantly high uveitis patient CME without CME . Inhibition inappropriate VEGF activity potential approach treatment CME uveitis give current knowledge pathophysiology condition also clinical need additional treatment option patient . Ranibizumab , recombinant , humanize monoclonal antibody antigen-binding fragment ( Fab ) neutralize active form VEGF-A , would target pathway may useful case persistent CME uveitis patient . The objective study determine anti-VEGF agent , Lucentis , safe effective lead regression macular edema due chronic non-infectious uveitis patient well-controlled uveitis .</brief_summary>
	<brief_title>Pilot Study Ranibizumab ( Lucentis ) Uveitic Cystoid Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : 1 . Ability provide write informed consent comply study assessment full duration study . 2 . Age &gt; 18 year 3 . Noninfectious uveitis study eye . 4 . Stable antiuveitis medical regimen least one month prior injection control uveitis judgment investigator . 5 . Vision 20/40 worse study eye . 6 . Cystoid Macular Edema ( CME ) fluorescein angiography ( FA ) 7 . Optical Coherence Tomography ( OCT ) demonstrate thickness great 300 micron central subfield . 8 . Media clarity , pupillary dilation patient cooperation sufficient allow OCT test retinal photography . Only one eye assess study . If eye eligible , investigator determine eye enter study . 1 . Previous intravitreal triamcinolone injection study eye within 3 month study injection . 2 . Use two glaucoma medicine study eye . 3 . Significant epiretinal membrane judge treat physician . 4 . Evidence vitreomacular traction OCT. 5 . Previous vitrectomy study eye . 6 . Pregnancy ( positive pregnancy test ) lactation . 7 . Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , intrauterine device ( IUD ) , contraceptive hormone implant patch . 8 . Any condition investigator believe would pose significant hazard subject investigational therapy initiate . 9 . Participation another simultaneous IND trial . 10 . Treatment CME intravitreal Lucentis , Macugen , Avastin within 6 week prior enrollment study . 11 . Uncontrolled inflammation study eye . 12 . Current vitreous hemorrhage . 13 . Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye . 14 . Known allergy component study drug . 15 . Intraocular pressure &gt; 25 mm Hg despite treatment glaucoma medication . 16 . Blood pressure &gt; 180/110 ( systolic 180 OR diastolic 110 ) . If blood pressure bring 180/110 antihypertensive treatment , subject become eligible . 17 . Major nonocular surgery plan next 6 month . 18 . Any condition investigator believe would pose significant hazard subject investigational therapy initiate . 19 . No Avastin use permit fellow eye study . 20 . Unwilling unable follow comply study relate procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Cystoid Macular Edema</keyword>
</DOC>